Chemotherapy in Metastatic NSCLC â€“ New Regimens (Pemetrexed, Nab-Paclitaxel)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Chemotherapy in Metastatic NSCLC â€“ New Regimens (Pemetrexed, Nab-Paclitaxel)

Published:2014-07-21 Issue: Volume:4 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Blais Normand,Hirsh Vera

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference50 articles.

1. Nonâ€“small cell lung cancer, version 2.2013;Ettinger;J Natl Compr Canc Netw,2013

2. American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small cell lung cancer;Azzoli;J Clin Oncol,2009

3. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer;Schiller;N Engl J Med,2002

4. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial;Kelly;J Clin Oncol,2001

5. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small cell lung cancer;Scagliotti;J Clin Oncol,2008

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Stage IV Non-small Cell Lung Cancer;Respiratory Medicine;2023

2. First‐line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non‐squamous non‐small cell lung cancer with wild‐type driver genes: A real‐world study in China;Thoracic Cancer;2019-03-22

3. Oxymatrine and Cisplatin Synergistically Enhance Anti-tumor Immunity of CD8+ T Cells in Non-small Cell Lung Cancer;Frontiers in Oncology;2018-12-18

4. Nanoparticle-Based Drugs: A Potential Armamentarium of Effective Anti-Cancer Therapies;Current Drug Metabolism;2018-09-14

5. Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis;Future Oncology;2015-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3